(Q36182754)

12 August 2017

1 reference

title

Modern diagnosis and treatment of primary eosinophilia (English)

1 reference

12 August 2017

1

A Tefferi

1 reference

12 August 2017

publication date

1 January 2005

1 reference

12 August 2017

1 reference

12 August 2017

volume

114

1 reference

12 August 2017

issue

1

1 reference

12 August 2017

page(s)

52-60

1 reference

The eosinophilias, including the idiopathic hypereosinophilic syndrome

12 August 2017

cites work

1 reference

Acute myelogenous leukemia (FAB M1) associated with t(5;16) and eosinophilia. Report of an additional case

21 January 2018

1 reference

Myelodysplastic syndrome with clonal eosinophilia accompanied by eosinophilic pulmonary interstitial infiltration

21 January 2018

1 reference

Chronic myelocytic leukemia with eosinophilia, t(9;12)(q34;p13), and ETV6-ABL gene rearrangement: case report and review of the literature

21 January 2018

1 reference

Cloning of the t(1;5)(q23;q33) in a myeloproliferative disorder associated with eosinophilia: involvement of PDGFRB and response to imatinib

21 January 2018

1 reference

Cytogenetic and molecular genetic aspects of eosinophilic leukaemias

21 January 2018

1 reference

Eosinophilia in systemic mastocytosis.

21 January 2018

1 reference

Relationship between idiopathic hypereosinophilic syndrome, eosinophilic leukemia, and systemic mastocytosis

21 January 2018

1 reference

FIP1L1-PDGFRA fusion: prevalence and clinicopathologic correlates in 89 consecutive patients with moderate to severe eosinophilia

21 January 2018

1 reference

Myeloproliferative disorders with translocations of chromosome 5q31-35: role of the platelet-derived growth factor receptor Beta

21 January 2018

1 reference

The 8p11 myeloproliferative syndrome: a distinct clinical entity caused by constitutive activation of FGFR1

21 January 2018

1 reference

Unexplained hypereosinophilia and the need for cytogenetic and molecular genetic analyses

21 January 2018

1 reference

Incidence of peripheral blood eosinophilia and the threshold eosinophile count for indicating hypereosinophilia-associated diseases.

21 January 2018

1 reference

Response to imatinib mesylate in patients with chronic myeloproliferative diseases with rearrangements of the platelet-derived growth factor receptor beta

21 January 2018

1 reference

Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia

21 January 2018

1 reference

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

CHIC2 deletion, a surrogate for FIP1L1-PDGFRA fusion, occurs in systemic mastocytosis associated with eosinophilia and predicts response to imatinib mesylate therapy

21 January 2018

1 reference

Immunophenotypic normalization of aberrant mast cells accompanies histological remission in imatinib-treated patients with eosinophilia-associated mastocytosis

21 January 2018

1 reference

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness

21 January 2018

1 reference

Noncardiovascular findings associated with heart disease in the idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

The spectrum of eosinophilic lung disease: radiologic findings

21 January 2018

1 reference

Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.

21 January 2018

1 reference

Serum concentration of cardiac Troponin T in patients with hypereosinophilic syndrome treated with imatinib is predictive of adverse outcomes.

21 January 2018

1 reference

Clinical and echocardiographic features of hypereosinophilic syndromes

21 January 2018

1 reference

Imatinib mesylate--a new oral targeted therapy

21 January 2018

1 reference

FIP1L1-PDGFRalpha in hypereosinophilic syndrome and mastocytosis

21 January 2018

1 reference

Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.

21 January 2018

1 reference

Molecular remission and reversal of myelofibrosis in response to imatinib mesylate treatment in patients with the myeloproliferative variant of hypereosinophilic syndrome

21 January 2018

1 reference

Complete molecular remission of chronic eosinophilic leukemia complicated by CNS disease after targeted therapy with imatinib

21 January 2018

1 reference

Sustained molecular response with imatinib in a leukemic form of idiopathic hypereosinophilic syndrome in relapse after allograft.

21 January 2018

1 reference

Chronic myeloproliferative disorders with rearrangement of the platelet-derived growth factor alpha receptor: a new clinical target for STI571/Glivec

21 January 2018

1 reference

Molecular and cytogenetic characterization of a novel translocation t(4;22) involving the breakpoint cluster region and platelet-derived growth factor receptor-alpha genes in a patient with atypical chronic myeloid leukemia

21 January 2018

1 reference

Reversal of hypereosinophilic syndrome and lymphomatoid papulosis with mepolizumab and imatinib

21 January 2018

1 reference

Reversal of cardiac abnormalities in a young man with idiopathic hypereosinophilic syndrome using a tyrosine kinase inhibitor

21 January 2018

1 reference

Imatinib therapy for hypereosinophilic syndrome and other eosinophilic disorders

21 January 2018

1 reference

Oligospermia in a patient receiving imatinib therapy for the hypereosinophilic syndrome

21 January 2018

1 reference

Activity of STI571 in chronic myelomonocytic leukemia with a platelet-derived growth factor beta receptor fusion oncogene

21 January 2018

1 reference

A 2-year-old with atypical CML with a t(5;12)(q33;p13) treated successfully with imatinib mesylate

21 January 2018

1 reference

Fusion of PDGF receptor beta to a novel ets-like gene, tel, in chronic myelomonocytic leukemia with t(5;12) chromosomal translocation

21 January 2018

1 reference

Novel translocations that disrupt the platelet-derived growth factor receptor beta (PDGFRB) gene in BCR-ABL-negative chronic myeloproliferative disorders.

21 January 2018

1 reference

Chronic eosinophilic leukaemia presenting with erythroderma, mild eosinophilia and hyper-IgE: clinical, immunological and cytogenetic features and therapeutic approach. A case report

21 January 2018

1 reference

Receptor tyrosine kinase mutations in myeloid neoplasms

21 January 2018

1 reference

Further evidence for the clonal nature of the idiopathic hypereosinophilic syndrome: complete haematological and cytogenetic remission induced by interferon-alpha in a case with a unique chromosomal abnormality.

21 January 2018

1 reference

Clinical and cytogenetic remission induced by interferon-alpha in a patient with chronic eosinophilic leukemia associated with a unique t(3;9;5) translocation

21 January 2018

1 reference

PKC412 inhibits the zinc finger 198-fibroblast growth factor receptor 1 fusion tyrosine kinase and is active in treatment of stem cell myeloproliferative disorder

21 January 2018

1 reference

Imatinib for systemic mast-cell disease

21 January 2018

1 reference

The biology of the eosinophilic leukocyte

21 January 2018

1 reference

Mechanism of membrane damage mediated by human eosinophil cationic protein

21 January 2018

1 reference

Neurotoxicity of human eosinophils towards peripheral nerves

21 January 2018

1 reference

Interferon-alpha in the idiopathic hypereosinophilic syndrome: consideration of five cases.

21 January 2018

1 reference

Interferon-alpha treatment of six patients with the idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Complete remission of hypereosinophilic syndrome after interferon-alpha therapy: report of a case and literature review

21 January 2018

1 reference

Cyclosporin for hypereosinophilic syndrome

21 January 2018

1 reference

Treatment of hypereosinophilic syndrome with imatinib mesilate

21 January 2018

1 reference

Response of idiopathic hypereosinophilic syndrome to treatment with imatinib mesylate

21 January 2018

1 reference

Efficacy of imatinib mesylate in the treatment of idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Effective treatment of hypereosinophilic syndrome with imatinib mesylate

21 January 2018

1 reference

Heterogeneity of response to imatinib-mesylate (glivec) in patients with hypereosinophilic syndrome: implications for dosing and pathogenesis

21 January 2018

1 reference

Successful treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate: a case report

21 January 2018

1 reference

Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Complete remission of an idiopathic hypereosinophilic syndrome while using imatinib

21 January 2018

1 reference

Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome

21 January 2018

1 reference

Alemtuzumab therapy for refractory idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Allogeneic bone marrow transplantation in a patient with hypereosinophilic syndrome

21 January 2018

1 reference

Allogeneic bone marrow transplantation for hypereosinophilic syndrome with advanced myelofibrosis.

21 January 2018

1 reference

Allogeneic blood stem cell transplantation following non-myeloablative conditioning for hypereosinophilic syndrome

21 January 2018

1 reference

Successful non-myeloablative allogeneic transplantation for treatment of idiopathic hypereosinophilic syndrome

21 January 2018

1 reference

Hypereosinophilic syndrome: long-term remission following allogeneic stem cell transplant in spite of transient eosinophilia post-transplant

21 January 2018

1 reference

Successful treatment with imatinib mesylate of hypereosinophilic syndrome (chronic eosinophilic leukemia) with myelofibrosis

21 January 2018

1 reference

Highly purified murine interleukin 5 (IL-5) stimulates eosinophil function and prolongs in vitro survival. IL-5 as an eosinophil chemotactic factor

21 January 2018

1 reference

Treatment of the Hypereosinophilic Syndrome with Interferon-α

21 January 2018

1 reference

Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti–IL-5 antibody SCH55700

21 January 2018

1 reference

21 January 2018

Identifiers

DOI

10.1159/000085562

1 reference

12 August 2017

1 reference